Dr. Hinchcliff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
250 E Superior St
Ste 4-420
Chicago, IL 60611Phone+1 312-695-0990Fax+1 312-472-4784
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2021
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Obstetrics and Gynecology, 2013 - 2017
Harvard Medical SchoolClass of 2013
The University of Texas Public Health SchoolMPH
Certifications & Licensure
IL State Medical License 2021 - 2026
TX State Medical License 2019 - 2023
MA State Medical License 2013 - 2017- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Publications & Presentations
PubMed
- Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer.Anne Knisely, Emily M Hinchcliff, Elisabeth Gardiner, Reshma Rangwala, Kathryn Lito
Iscience. 2024-05-17 - 3 citationsPhase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis.Anne Knisely, Emily Hinchcliff, Bryan Fellman, Ann Mosley, Kathryn Lito
Med. 2024-04-12 - 3 citationsRandomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.Emily M Hinchcliff, Anne Knisely, Naomi Adjei, Bryan Fellman, Ying Yuan
Cancer. 2024-04-01
Press Mentions
Uterine Cancer Cases Are Rising. Here’s What to KnowOctober 25th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
